Blood Cancers
FDA Approves Ruxolitinib for GVHD Treatment
BY BRIELLE BENYON
FDA Approves Venetoclax Plus Obinutuzumab for CLL Treatment
BY ONCLIVE STAFF
Looking Ahead: FDA Actions on Breast Implant-Associated Cancer
BY BRIELLE BENYON
FDA Approves Ivosidenib for Frontline Acute Myeloid Leukemia
BY GINA COLUMBUS
New Agents Spark Excitement in Myeloma Space
BY KRISTI ROSA
Sticking to a Checklist Ensures Proper Administration of CAR-T Cell Therapies
BY BETH FAND INCOLLINGO
FDA Demands More Information on Cancer and Illnesses Caused by Breast Implants
BY BETH FAND INCOLLINGO
Disparities Exist in Delivering Innovative Cancer Therapies
BY JOHN SWEETENHAM, MD, FACP, FRCP
External Resources
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.